http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Y.C. Li,M.H. Li,M. Wang,L. Liu,X.J. Zhang,C.M. Qin,Y.F. Wang,C.B. Wu,L.N. Liu,J.C. Xu,B. J. Ding,X. D. Lin,B. J. Ding,X. D. Lin,J. F. Shan,F. K. Liu,Y. P. Zhao,T. Zhang,X. Gao 한국원자력학회 2022 Nuclear Engineering and Technology Vol.54 No.1
The suppression of high-intensity blob structures in the scrape-off layer (SOL) by ion-cyclotron range offrequencies (ICRF) power, leading to a decrease in the turbulent fluctuation level, is observed first in theExperimental Advanced Superconducting Tokamak (EAST) experiment. This suppression effect from ICRFpower injection is global in the whole SOL at EAST, i.e. blob structures both in the regions that aremagnetically connected to the active ICRF launcher and in the regions that are not connected to theactive ICRF launcher could be suppressed by ICRF power. However, more ICRF power is required to reachthe full blob structure suppression effect in the regions that are magnetically unconnected to the activelauncher than in the regions that are magnetically connected to the active launcher. Studies show that apossible reason for the blob suppression could be the enhanced Er B shear flow in the SOL, which issupported by the shaper radial gradient in the floating potential profiles sensed by the divertor probearrays with increasing ICRF power. The local RF wave power unabsorbed by the core plasma isresponsible for the modification of potential profiles in the SOL regions.
Near-UV-emitting graphene quantum dots from graphene hydrogels
Qin, H.,Gong, T.,Jin, Y.,Cho, Y.,Shin, C.,Lee, C.,Kim, T. Pergamon Press ; Elsevier Science Ltd 2015 Carbon Vol.94 No.-
We report a novel method to prepare graphene quantum dots (GQDs) from graphene hydrogels. Graphene hydrogels were prepared using a hydrothermal technique, and GQDs were released from the hydrogels on immersion of the hydrogels in low-polarity organic solvents. This method did not require additional treatments such as the centrifugation, filtration and dialysis typical of the general hydrothermal method. These GQDs were observed to fluoresce, with their strongest emission in the near-UV region, at ~347nm. Moreover, these GQDs, when in their pure state, formed a highly viscous liquid insoluble in water due to their lack of many oxygen-containing functional groups.
Qin, L.,Wei, D.,Huang, Y.,Kim, S.I.,Yu, Y.M.,Seo, H.J. Elsevier Sequoia 2013 Journal of alloys and compounds Vol.574 No.-
Eulytite-type orthophosphates M<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>6</SUB> (M=Ca, Sr, Ba) were prepared by conventional high temperature solid-state reaction. Sr<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>6</SUB> and Ba<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>6</SUB> crystallize in the pure eulytite-type phase with cubic space group (I4@?3d). The impurity phase β-Ca<SUB>3</SUB>(PO<SUB>4</SUB>)<SUB>2</SUB> was inevitably coexisted with the Ca<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>6</SUB> phase. The luminescence properties are investigated by UV-VUV excitation and emission spectroscopy and X-ray-excited luminescence (XEL) spectroscopy. The broad excitation and emission bands are observed due to the charge transfer transition from Zr<SUP>4+</SUP> to O<SUP>2-</SUP> in M<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>6</SUB> (M=Ca, Sr, Ba) eulytite. The characteristics of the phosphors including the luminescence mechanism are explained by Stokes shift, decay curves, and CIE color coordinates. The Sr<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>3</SUB> and Ba<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>3</SUB> phosphors exhibit unusual spectral features with the emission bands at 470 and 480nm, respectively. The weak luminescence centered at 495nm is observed in the Ca<SUB>7</SUB>Zr(PO<SUB>4</SUB>)<SUB>6</SUB> eulytite with lifetime of 4.67μs. The unusual self-activated luminescence is discussed on the base of the crystal structure of eulytite.
Effect of surface modification layer thickness on the gas sensitivity of SnO2 films
Y.H. Xiong,L. Wang,X.Y. Wei,G.R. Qin,C.H. Mao,J. Du 한양대학교 세라믹연구소 2006 Journal of Ceramic Processing Research Vol.7 No.4
Nickel was used as a surface modification material to enhance the gas-sensing properties of SnO2 films. The thickness of the Ni modification layer was controlled by the sputtering time. The surface morphology and surface chemical composition of the surface modification layers of different thicknesses were analyzed by Field Emission Scanning Electron Microscopy (FESEM) and X-ray Photoelectron Spectroscopy (XPS), respectively. The gas sensitivity to clean air with a low hydrogen concentration of 1000 ppm of the modified tin dioxide thin films was investigated at temperatures from 20oC to 100oC. The results show that the thickness of the modification layer plays an important role in the enhancement of the gas-sensing properties and surface electric properties of SnO2 films. A Ni modification layer with a thickness of 50 nm on the surface of a SnO2 film can improve the hydrogen gas sensitivity of a SnO2 film up to 112%, and reduce the response time to 80s. Nickel was used as a surface modification material to enhance the gas-sensing properties of SnO2 films. The thickness of the Ni modification layer was controlled by the sputtering time. The surface morphology and surface chemical composition of the surface modification layers of different thicknesses were analyzed by Field Emission Scanning Electron Microscopy (FESEM) and X-ray Photoelectron Spectroscopy (XPS), respectively. The gas sensitivity to clean air with a low hydrogen concentration of 1000 ppm of the modified tin dioxide thin films was investigated at temperatures from 20oC to 100oC. The results show that the thickness of the modification layer plays an important role in the enhancement of the gas-sensing properties and surface electric properties of SnO2 films. A Ni modification layer with a thickness of 50 nm on the surface of a SnO2 film can improve the hydrogen gas sensitivity of a SnO2 film up to 112%, and reduce the response time to 80s.
Kang, Y.-K.,Yau, T.,Park, J.-W.,Lim, H. Y.,Lee, T.-Y.,Obi, S.,Chan, S. L.,Qin, SK.,Kim, R. D.,Casey, M.,Chen, C.,Bhattacharyya, H.,Williams, J. A.,Valota, O.,Chakrabarti, D.,Kudo, M. Oxford University Press 2015 Annals of oncology Vol.26 No.12
<P>Axitinib plus best supportive care failed to meet the primary end point of overall survival in second-line treatment of advanced hepatocellular carcinoma in a randomized phase II study. However, the axitinib arm showed substantially improved progression-free survival, time to tumour progression, and clinical benefit rate compared with the placebo arm, with acceptable safety profile. Background: The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Patients and methods: Patients with HCC and Child-Pugh Class A who progressed on or were intolerant to one prior antiangiogenic therapy were stratified by tumour invasion (presence/absence of extrahepatic spread and/or vascular invasion) and region (Asian/non-Asian) and randomized (2:1) to axitinib/BSC (starting dose 5 mg twice-daily) or placebo/BSC. The primary end point was overall survival (OS). Results: The estimated hazard ratio for OS was 0.907 [95% confidence interval (CI) 0.646-1.274; one-sided stratified P = 0.287] for axitinib/BSC (n = 134) versus placebo/BSC (n = 68), with the median (95% CI) of 12.7 (10.2-14.9) versus 9.7 (5.9-11.8) months, respectively. Results of prespecified subgroup analyses in Asian versus non-Asian patients or presence versus absence of tumour invasion were consistent with the overall population. Improvements favouring axitinib/BSC (P < 0.01) were observed in secondary efficacy end point analyses [progression-free survival (PFS), time to tumour progression (TTP), and clinical benefit rate (CBR)], and were retained among Asian patients in the prespecified subgroup analyses. Overall response rate did not differ significantly between treatments and patient-reported outcomes favoured placebo/BSC. Most common all-causality adverse events with axitinib/BSC were diarrhoea (54%), hypertension (54%), and decreased appetite (47%). Baseline serum analyses identified potential new prognostic (interleukin-6, E-selectin, interleukin-8, angiopoietin-2, migration inhibitory factor, and c-MET) or predictive (E-selectin and stromal-derived factor-1) factors for survival. Conclusions: Axitinib/BSC did not improve OS over placebo/BSC in the overall population or in stratification subgroups. However, axitinib/BSC resulted in significantly longer PFS and TTP and higher CBR, with acceptable toxicity in patients with advanced HCC. Trial Registration: ClinicalTrials.gov, NCT01210495.</P>